SRGN and breast cancer: Additionally, HDAC2 inhibition has also been found to strongly restrain the multidrug-resistance of BC cells induced by the SRGN (serglycin)–YAP (YES-associated protein) axis, therefore enhancing the therapeutic effect of chemotherapy [32].